Stimulator of interferon genes (STING) agonists, includingcyclicdinucleotides (CDNs), hold promise as adjuvants for cancer immunotherapydue to their capability to trigger the cyclic GMP–AMP synthase(cGAS)–STING pathway, thereby initiating tumor-specific adaptiveimmune responses.18−24 This pathway drives a comprehensive type I IFN response, promotingDC maturation and migration and priming cytotoxic T lymphocytes alongwith natural killer cells. This evidence concerns the gene STING1 and cancer.